What are the Key Market Barriers within Liquid Biopsy? Part 2 with Dennis Merkle, CEO of Predicine Europe.
In part two of this three-part discussion, Adam and Dennis discuss the key barriers for entry for companies expanding into new territories and how to overcome these, whether you're a start-up or established company entering the market. Dennis brings insight from his broad and brilliant background in molecular oncology and precision medicine, with experience in all elements from research to pharma and commercial. Discussing the challenges and opportunities he's faced as the CEO of Predicine in Europe. This conversation comes in three parts. In part one, the pair discussed the importance of liquid biopsy for the future oncology market. Part three discusses new liquid biopsy technologies and what's new at Predicine. Be sure to subscribe to be notified when all parts are available. If you'd like to get in touch about this episode, be a future podcast guest, or learn more about CM Life Science's services, please email Adam at [email protected].